Literature DB >> 33221211

NIRS-IVUS for Differentiating Coronary Plaque Rupture, Erosion, and Calcified Nodule in Acute Myocardial Infarction.

Kosei Terada1, Takashi Kubo2, Takeyoshi Kameyama1, Yoshiki Matsuo1, Yasushi Ino1, Hiroki Emori1, Daisuke Higashioka1, Yosuke Katayama1, Amir Kh M Khalifa1, Masahiro Takahata1, Kunihiro Shimamura1, Yasutsugu Shiono1, Atsushi Tanaka1, Takeshi Hozumi1, Ryan D Madder3, Takashi Akasaka1.   

Abstract

OBJECTIVES: This study sought to investigate the ability of combined near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS) to differentiate plaque rupture (PR), plaque erosion (PE), or calcified nodule (CN) in acute myocardial infarction (AMI).
BACKGROUND: Most acute coronary syndromes occur from coronary thrombosis based on PR, PE, or CN. In vivo differentiation among PR, PE, and CN is a major challenge for intravascular imaging.
METHODS: The study enrolled 244 patients with AMI who had a de novo culprit lesion in a native coronary artery. The culprit lesions were assessed by both NIRS-IVUS and optical coherence tomography (OCT). Maximum lipid core burden index in 4 mm (maxLCBI4mm) was measured by NIRS. Plaque cavity and convex calcium was detected by IVUS. The OCT diagnosis of PR (n = 175), PE (n = 44), and CN (n = 25) was used as a reference standard.
RESULTS: In the development cohort, IVUS-detected plaque cavity showed a high specificity (100%) and intermediate sensitivity (62%) for identifying OCT-PR. IVUS-detected convex calcium showed a high sensitivity (93%) and specificity (100%) for identifying OCT-CN. NIRS-measured maxLCBI4mm was largest in OCT-PR (705 [interquartile range (IQR): 545 to 854]), followed by OCT-CN (355 [IQR: 303 to 478]) and OCT-PE (300 [IQR: 126 to 357]) (p < 0.001). The optimal cutoff value of maxLCBI4mm was 426 for differentiating between OCT-PR and -PE; 328 for differentiating between OCT-PE and -CN; and 579 for differentiating between OCT-PR and -CN. In the validation cohort, the NIRS-IVUS classification algorithm using plaque cavity, convex calcium, and maxLCBI4mm showed a sensitivity and specificity of 97% and 96% for identifying OCT-PR, 93% and 99% for OCT-PE, and 100% and 99% for OCT-CN, respectively.
CONCLUSIONS: By evaluating plaque cavity, convex calcium, and maxLCBI4mm, NIRS-IVUS can accurately differentiate PR, PE, and CN.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  calcified nodule; intravascular ultrasound; near-infrared spectroscopy; optical coherence tomography; plaque erosion; plaque rupture

Year:  2020        PMID: 33221211     DOI: 10.1016/j.jcmg.2020.08.030

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  3 in total

1.  Predictors of Near-Infrared Spectroscopy-Detected Lipid-Rich Plaques by Optical Coherence Tomography-Defined Morphological Features in Patients With Acute Coronary Syndrome.

Authors:  Eisuke Usui; Taishi Yonetsu; Mari Ohmori; Yoshinori Kanno; Masahiko Nakao; Takayuki Niida; Yuji Matsuda; Junji Matsuda; Tomoyuki Umemoto; Toru Misawa; Masahiro Hada; Masahiro Hoshino; Yoshihisa Kanaji; Tomoyo Sugiyama; Tsunekazu Kakuta; Tetsuo Sasano
Journal:  Front Cardiovasc Med       Date:  2022-02-21

2.  Tissue characterisation and primary percutaneous coronary intervention guidance using intravascular ultrasound: rationale and design of the SPECTRUM study.

Authors:  Frederik T W Groenland; Karim D Mahmoud; Tara Neleman; Annemieke C Ziedses des Plantes; Alessandra Scoccia; Jurgen Ligthart; Karen T Witberg; Rutger-Jan Nuis; Wijnand K den Dekker; Jeroen M Wilschut; Roberto Diletti; Felix Zijlstra; Isabella Kardys; Paul Cummins; Nicolas M Van Mieghem; Joost Daemen
Journal:  Open Heart       Date:  2022-04

Review 3.  Combined Use of Multiple Intravascular Imaging Techniques in Acute Coronary Syndrome.

Authors:  Takashi Kubo; Kosei Terada; Yasushi Ino; Yasutsugu Shiono; Shengxian Tu; Tien-Ping Tsao; Yundai Chen; Duk-Woo Park
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.